Nurith Aizenman

How did the coronavirus end up mutating into the omicron variant? One hypothesis is that it spent months replicating in the body of someone whose immune system was suppressed by uncontrolled HIV.

Pharmaceutical companies Pfizer and Merck have agreed to allow generic manufacturers to make inexpensive versions of their anti-viral pills to treat COVID-19.

Wealthy countries keep buying way more doses than they need. New data shows just how much the stockpile of unused vaccine is growing.

There's been a massive ramp up in production of COVID-19 vaccines. Yet low income nations still aren't getting enough. Analysts say it's because wealthy countries are buying way more than they need.

It's the first step in an audacious plan to solve vaccine inequity by setting up the manufacturing of mRNA vaccines across low-resource countries,

A consortium in South Africa wants to teach manufacturers in poor countries to make Moderna's COVID vaccine. But Moderna won't share its process. So the scientists are trying to reverse engineer it.

President Biden has unveiled a plan to vaccinate 70% of the world's population over the next year. But what will it take to get other rich countries on board? And is the goal ambitious enough?

President Biden announced an effort to vaccinate 70% of the world's population against COVID by this time 2022. Health officials from lower income countries say they need more than donations of doses.

She's had to flee Afghanistan for her life. And she's one of many whose experience offers a window into what the Taliban takeover may hold for the country's women.

The Taliban say they'll guarantee the rights of Afghanistan's women, but their actions are already throwing that into doubt. One gynecologist fled the country 10 days ago because of death threats.

She's one of 110 girls in a boarding program run by the Veerni Institute in India. When lockdowns hit, they were sent home to their villages, where child marriage is rampant.

The World Health Organization has reported a downturn after 8 weeks of increasing cases. But the good news comes with a large dose of caution.

Africa just marked its worst pandemic week ever and its third wave of COVID-19 — largely driven by the delta variant. Vaccine shipments to the continent are moving slowly.

Vaccines may not be as effective for those who are immuno-compromised. Protecting them needs to be made a top priority, says researchers — to keep them safe and to slow the emergence of variants.

Thanks to widespread vaccinations, the U.S. is reopening. Meanwhile, countries without similar access to doses are angry and fearful — amid signs the COVID-19 catastrophe in India could spread.

African nations had been counting on Serum Institute of India for nearly all their COVID vaccines. Now the company says it won't be sending any more for months. And African officials are scrambling.

India's freeze on AstraZeneca exports is upending Africa's already limited vaccination progress, as the Africans who got their first dose are coming due for their second with no supply in sight.

How the chaotic system for distributing the world's vaccine supply is wreaking havoc in places that can least afford it.

While many African countries need more COVID-19 vaccines, others are struggling to administer the shots they have. Malawi and South Sudan have even had to throw out unused and expired doses.

One of the hottest areas of research right now: studies to determine how well current vaccines work against emerging coronavirus "variants of concern."